- Topline data expected as early as mid-2025 - SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the initiation of a Phase 1, open label, dose ranging clinical trial evaluating its second-generation oral norovirus vaccine constructs head-to-head against its first-generation constructs.
Robust, antigen-specific responses in the nasal cavity following oral administration underscore the efficiency of Vaxart's oral vaccine platform in generating mucosal antibody responses beyond the site of administration Robust, antigen-specific responses in the nasal cavity following oral administration underscore the efficiency of Vaxart's oral vaccine platform in generating mucosal antibody responses beyond the site of administration
Independent Data Safety Monitoring Board (DSMB) recommends study to proceed without modifications based on initial safety assessment of 400 participant 30-day data
VAXART, INC. (VXRT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.10.
Vaxart, Inc. (NASDAQ:VXRT ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Edward Berg - Senior Vice President and General Counsel Steven Lo - Chief Executive Officer James Cummings - Chief Medical Officer Sean Tucker - Senior Vice President and Chief Scientific Officer Phillip Lee - Chief Financial Officer Conference Call Participants Cheng Li - Oppenheimer Mayank Mamtani - B. Riley Securities Liang Cheng - Jefferies Operator Greetings and welcome to the Vaxart Business Update and Third Quarter 2024 Financial Results Conference Call.
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on August 26, 2024, the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 32,250 shares of its common stock to two new non-executive employees to induce them to accept employment with Vaxart.
Oppenheimer initiated coverage on Vaxart Inc. VXRT, an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines.
VAXART, INC. (VXRT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of $0.03.
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and norovirus programs — SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today provided business and cash runway updates as the Company continues to advance its oral pill vaccine platform.